Jpmorgan Chase & CO Kamada LTD Transaction History

Jpmorgan Chase & CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$4.78 - $5.75 $141,339 - $170,021	29,569 Added 24.16%	151,949 $753,000
Q1 2024 May 10, 2024	BUY	$5.58 - $6.42 $606,585 - $697,898	108,707 Added 795.05%	122,380 $686,000
Q4 2023 Feb 12, 2024	BUY	$4.14 - $6.22 $56,606 - $85,046	13,673 New	13,673 $83,000
Q2 2023 Aug 11, 2023	BUY	$4.48 - $5.53 $70,900 - $87,517	15,826 New	15,826 $83,000
Q3 2022 Nov 14, 2022	SELL	$4.42 - $5.43 $31,828 - $39,101	-7,201 Reduced 20.01%	28,787 $130,000
Q2 2022 Aug 11, 2022	SELL	$4.22 - $5.85 $54,286 - $75,254	-12,864 Reduced 26.33%	35,988 $162,000
Q1 2022 May 11, 2022	SELL	$5.43 - $6.81 $217,547 - $272,835	-40,064 Reduced 45.06%	48,852 $269,000
Q4 2021 Feb 10, 2022	SELL	$5.21 - $6.82 $121,247 - $158,715	-23,272 Reduced 20.74%	88,916 $585,000
Q3 2021 Nov 12, 2021	BUY	$5.25 - $5.87 $588,987 - $658,543	112,188 New	112,188 $595,000

6.48M

200

Ticker KMDA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 44,800,500
Market Cap $264M
Description
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.